Severity of comorbid conditions and early-stage breast cancer therapy: Linked SEER-medicare data from 1993 to 2005

Shagufta Yasmeen, Rowan T. Chlebowski, Guibo Xing, Cyllene R. Morris, Patrick S Romano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Comorbidity burden has been suggested as influencing early-stage breast cancer therapy but previous studies have not considered the severity of these comorbidities. Therefore, we examined the influence of comorbidity severity by age and race/ethnicity on early-stage breast cancer treatment over time. We used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data to determine whether comorbidity severity influences receipt of definitive and preferred early-stage breast cancer treatment and explains racial/ethnic and age disparities in receiving such therapy. Definitive surgical therapy was defined as any primary surgery other than breast conserving surgery (BCS) without radiation therapy (RT). Preferred surgical therapy was defined as BCS plus RT. Comorbidities were defined as either "unstable" (life threatening or difficult to control) or "stable" (less serious but with potential to influence daily activity). Surgical treatment trends from 1993 to 2005 were analyzed in regression models adjusting for comorbidity burden, age, and race/ethnicity in 93,596 elderly female Medicare beneficiaries with stage 1-2 invasive breast cancer. Receipt of BCS alone (compared with any definitive surgical therapy) was independently associated with neighborhood socioeconomic status, unmarried status (OR [odds ratio] 1.18, 95% CI: 1.12-1.23), tumor size (OR 0.78, 95% CI: 0.69-0.87 for tumors ≥4 cm vs. <2 cm), tumor grade (OR = 0.89, 0.88, and 0.81 for grades 2-4 vs. 1, respectively), stable comorbidities (OR = 0.76, 0.71, and 0.72 for 1, 2, and 3 vs. 0 stable comorbidities, respectively), and unstable comorbidities (OR 1.20, 95% CI: 1.14-1.28). Black women were 4-5% more likely to receive suboptimal therapy (BCS alone), even after adjusting for all available patient, tumor, and regional characteristics. Black race/ethnicity was associated with higher probability of receiving suboptimal treatment, independent of comorbidities, although we do not know whether this effect was due to clinicians' failure to offer RT or patients' failure to accept it.

Original languageEnglish (US)
Pages (from-to)526-536
Number of pages11
JournalCancer Medicine
Volume2
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Medicare
Comorbidity
Epidemiology
Breast Neoplasms
Segmental Mastectomy
Therapeutics
Radiotherapy
Neoplasms
Social Class
Odds Ratio

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Severity of comorbid conditions and early-stage breast cancer therapy : Linked SEER-medicare data from 1993 to 2005. / Yasmeen, Shagufta; Chlebowski, Rowan T.; Xing, Guibo; Morris, Cyllene R.; Romano, Patrick S.

In: Cancer Medicine, Vol. 2, No. 4, 2013, p. 526-536.

Research output: Contribution to journalArticle

Yasmeen, Shagufta ; Chlebowski, Rowan T. ; Xing, Guibo ; Morris, Cyllene R. ; Romano, Patrick S. / Severity of comorbid conditions and early-stage breast cancer therapy : Linked SEER-medicare data from 1993 to 2005. In: Cancer Medicine. 2013 ; Vol. 2, No. 4. pp. 526-536.
@article{bc4450a471904405bdb313a6703f8755,
title = "Severity of comorbid conditions and early-stage breast cancer therapy: Linked SEER-medicare data from 1993 to 2005",
abstract = "Comorbidity burden has been suggested as influencing early-stage breast cancer therapy but previous studies have not considered the severity of these comorbidities. Therefore, we examined the influence of comorbidity severity by age and race/ethnicity on early-stage breast cancer treatment over time. We used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data to determine whether comorbidity severity influences receipt of definitive and preferred early-stage breast cancer treatment and explains racial/ethnic and age disparities in receiving such therapy. Definitive surgical therapy was defined as any primary surgery other than breast conserving surgery (BCS) without radiation therapy (RT). Preferred surgical therapy was defined as BCS plus RT. Comorbidities were defined as either {"}unstable{"} (life threatening or difficult to control) or {"}stable{"} (less serious but with potential to influence daily activity). Surgical treatment trends from 1993 to 2005 were analyzed in regression models adjusting for comorbidity burden, age, and race/ethnicity in 93,596 elderly female Medicare beneficiaries with stage 1-2 invasive breast cancer. Receipt of BCS alone (compared with any definitive surgical therapy) was independently associated with neighborhood socioeconomic status, unmarried status (OR [odds ratio] 1.18, 95{\%} CI: 1.12-1.23), tumor size (OR 0.78, 95{\%} CI: 0.69-0.87 for tumors ≥4 cm vs. <2 cm), tumor grade (OR = 0.89, 0.88, and 0.81 for grades 2-4 vs. 1, respectively), stable comorbidities (OR = 0.76, 0.71, and 0.72 for 1, 2, and 3 vs. 0 stable comorbidities, respectively), and unstable comorbidities (OR 1.20, 95{\%} CI: 1.14-1.28). Black women were 4-5{\%} more likely to receive suboptimal therapy (BCS alone), even after adjusting for all available patient, tumor, and regional characteristics. Black race/ethnicity was associated with higher probability of receiving suboptimal treatment, independent of comorbidities, although we do not know whether this effect was due to clinicians' failure to offer RT or patients' failure to accept it.",
author = "Shagufta Yasmeen and Chlebowski, {Rowan T.} and Guibo Xing and Morris, {Cyllene R.} and Romano, {Patrick S}",
year = "2013",
doi = "10.1002/cam4.66",
language = "English (US)",
volume = "2",
pages = "526--536",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Severity of comorbid conditions and early-stage breast cancer therapy

T2 - Linked SEER-medicare data from 1993 to 2005

AU - Yasmeen, Shagufta

AU - Chlebowski, Rowan T.

AU - Xing, Guibo

AU - Morris, Cyllene R.

AU - Romano, Patrick S

PY - 2013

Y1 - 2013

N2 - Comorbidity burden has been suggested as influencing early-stage breast cancer therapy but previous studies have not considered the severity of these comorbidities. Therefore, we examined the influence of comorbidity severity by age and race/ethnicity on early-stage breast cancer treatment over time. We used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data to determine whether comorbidity severity influences receipt of definitive and preferred early-stage breast cancer treatment and explains racial/ethnic and age disparities in receiving such therapy. Definitive surgical therapy was defined as any primary surgery other than breast conserving surgery (BCS) without radiation therapy (RT). Preferred surgical therapy was defined as BCS plus RT. Comorbidities were defined as either "unstable" (life threatening or difficult to control) or "stable" (less serious but with potential to influence daily activity). Surgical treatment trends from 1993 to 2005 were analyzed in regression models adjusting for comorbidity burden, age, and race/ethnicity in 93,596 elderly female Medicare beneficiaries with stage 1-2 invasive breast cancer. Receipt of BCS alone (compared with any definitive surgical therapy) was independently associated with neighborhood socioeconomic status, unmarried status (OR [odds ratio] 1.18, 95% CI: 1.12-1.23), tumor size (OR 0.78, 95% CI: 0.69-0.87 for tumors ≥4 cm vs. <2 cm), tumor grade (OR = 0.89, 0.88, and 0.81 for grades 2-4 vs. 1, respectively), stable comorbidities (OR = 0.76, 0.71, and 0.72 for 1, 2, and 3 vs. 0 stable comorbidities, respectively), and unstable comorbidities (OR 1.20, 95% CI: 1.14-1.28). Black women were 4-5% more likely to receive suboptimal therapy (BCS alone), even after adjusting for all available patient, tumor, and regional characteristics. Black race/ethnicity was associated with higher probability of receiving suboptimal treatment, independent of comorbidities, although we do not know whether this effect was due to clinicians' failure to offer RT or patients' failure to accept it.

AB - Comorbidity burden has been suggested as influencing early-stage breast cancer therapy but previous studies have not considered the severity of these comorbidities. Therefore, we examined the influence of comorbidity severity by age and race/ethnicity on early-stage breast cancer treatment over time. We used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data to determine whether comorbidity severity influences receipt of definitive and preferred early-stage breast cancer treatment and explains racial/ethnic and age disparities in receiving such therapy. Definitive surgical therapy was defined as any primary surgery other than breast conserving surgery (BCS) without radiation therapy (RT). Preferred surgical therapy was defined as BCS plus RT. Comorbidities were defined as either "unstable" (life threatening or difficult to control) or "stable" (less serious but with potential to influence daily activity). Surgical treatment trends from 1993 to 2005 were analyzed in regression models adjusting for comorbidity burden, age, and race/ethnicity in 93,596 elderly female Medicare beneficiaries with stage 1-2 invasive breast cancer. Receipt of BCS alone (compared with any definitive surgical therapy) was independently associated with neighborhood socioeconomic status, unmarried status (OR [odds ratio] 1.18, 95% CI: 1.12-1.23), tumor size (OR 0.78, 95% CI: 0.69-0.87 for tumors ≥4 cm vs. <2 cm), tumor grade (OR = 0.89, 0.88, and 0.81 for grades 2-4 vs. 1, respectively), stable comorbidities (OR = 0.76, 0.71, and 0.72 for 1, 2, and 3 vs. 0 stable comorbidities, respectively), and unstable comorbidities (OR 1.20, 95% CI: 1.14-1.28). Black women were 4-5% more likely to receive suboptimal therapy (BCS alone), even after adjusting for all available patient, tumor, and regional characteristics. Black race/ethnicity was associated with higher probability of receiving suboptimal treatment, independent of comorbidities, although we do not know whether this effect was due to clinicians' failure to offer RT or patients' failure to accept it.

UR - http://www.scopus.com/inward/record.url?scp=84902080012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902080012&partnerID=8YFLogxK

U2 - 10.1002/cam4.66

DO - 10.1002/cam4.66

M3 - Article

C2 - 24156025

AN - SCOPUS:84902080012

VL - 2

SP - 526

EP - 536

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -